DaVita Target of Unusually High Options Trading (NYSE:DVA)

DaVita Inc. (NYSE:DVA) was the target of some unusual options trading on Friday. Traders acquired 11,404 call options on the company. This represents an increase of 508% compared to the typical volume of 1,875 call options.

Institutional Trading of DaVita

Institutional investors have recently made changes to their positions in the company. Value Investment Professionals LLC lifted its position in DaVita by 2.0% during the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after acquiring an additional 50 shares during the period. Kesler Norman & Wride LLC boosted its stake in shares of DaVita by 0.8% during the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after purchasing an additional 55 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of DaVita by 4.1% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock worth $426,000 after buying an additional 76 shares in the last quarter. Root Financial Partners LLC lifted its stake in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares during the last quarter. Finally, IFP Advisors Inc boosted its holdings in DaVita by 32.4% in the second quarter. IFP Advisors Inc now owns 437 shares of the company’s stock worth $97,000 after acquiring an additional 107 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 0.7%

NYSE:DVA traded down $1.33 during midday trading on Friday, hitting $181.76. 156,183 shares of the company traded hands, compared to its average volume of 918,086. DaVita has a 12-month low of $101.00 and a 12-month high of $247.49. The firm’s fifty day moving average is $200.58 and its 200-day moving average is $186.72. The firm has a market capitalization of $11.60 billion, a P/E ratio of 14.85, a P/E/G ratio of 0.50 and a beta of 0.83.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita will post 14.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on DVA shares. Oppenheimer set a $220.00 price objective on DaVita in a research note on Friday, August 7th. UBS Group raised their price target on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Barclays boosted their price objective on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Finally, Truist Financial decreased their price objective on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.